> top > docs > PubMed:21658240 > annotations

PubMed:21658240 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-221 Sentence denotes Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.
T2 222-235 Sentence denotes INTRODUCTION:
T3 236-391 Sentence denotes Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/γ-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury.
T4 392-615 Sentence denotes EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury.
T5 616-1135 Sentence denotes This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation).
T6 1136-1315 Sentence denotes Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
T7 1316-1324 Sentence denotes METHODS:
T8 1325-1504 Sentence denotes Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids.
T9 1505-1595 Sentence denotes Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3.
T10 1596-1721 Sentence denotes To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed.
T11 1722-1791 Sentence denotes All clinical outcomes were recorded during a 28-day follow-up period.
T12 1792-1800 Sentence denotes RESULTS:
T13 1801-1924 Sentence denotes A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable.
T14 1925-2240 Sentence denotes Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217).
T15 2241-2487 Sentence denotes The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group.
T16 2488-2707 Sentence denotes Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04).
T17 2708-2847 Sentence denotes The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients:
T18 2848-2912 Sentence denotes 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients:
T19 2913-2958 Sentence denotes 17.5% versus 34.5%, respectively; P = 0.295).
T20 2959-3073 Sentence denotes Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients:
T21 3074-3165 Sentence denotes 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients:
T22 3166-3283 Sentence denotes 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients:
T23 3284-3385 Sentence denotes 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients:
T24 3386-3500 Sentence denotes 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means).
T25 3501-3586 Sentence denotes No significant differences in 28-day all-cause mortality were observed (ITT patients:
T26 3587-3667 Sentence denotes 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable:
T27 3668-3737 Sentence denotes 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
T28 3738-3750 Sentence denotes CONCLUSIONS:
T29 3751-4069 Sentence denotes These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
T30 4070-4089 Sentence denotes TRIAL REGISTRATION:
T31 4090-4122 Sentence denotes ClinicalTrials.gov: NCT00981877.
T1 0-221 Sentence denotes Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.
T2 222-235 Sentence denotes INTRODUCTION:
T3 236-391 Sentence denotes Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/γ-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury.
T4 392-615 Sentence denotes EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury.
T5 616-1135 Sentence denotes This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation).
T6 1136-1315 Sentence denotes Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
T7 1316-1324 Sentence denotes METHODS:
T8 1325-1504 Sentence denotes Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids.
T9 1505-1595 Sentence denotes Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3.
T10 1596-1721 Sentence denotes To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed.
T11 1722-1791 Sentence denotes All clinical outcomes were recorded during a 28-day follow-up period.
T12 1792-1800 Sentence denotes RESULTS:
T13 1801-1924 Sentence denotes A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable.
T14 1925-2240 Sentence denotes Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217).
T15 2241-2487 Sentence denotes The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group.
T16 2488-2707 Sentence denotes Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04).
T17 2708-2847 Sentence denotes The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients:
T18 2848-2912 Sentence denotes 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients:
T19 2913-2958 Sentence denotes 17.5% versus 34.5%, respectively; P = 0.295).
T20 2959-3073 Sentence denotes Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients:
T21 3074-3165 Sentence denotes 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients:
T22 3166-3283 Sentence denotes 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients:
T23 3284-3385 Sentence denotes 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients:
T24 3386-3500 Sentence denotes 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means).
T25 3501-3586 Sentence denotes No significant differences in 28-day all-cause mortality were observed (ITT patients:
T26 3587-3667 Sentence denotes 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable:
T27 3668-3737 Sentence denotes 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
T28 3738-3750 Sentence denotes CONCLUSIONS:
T29 3751-4069 Sentence denotes These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
T30 4070-4089 Sentence denotes TRIAL REGISTRATION:
T31 4090-4122 Sentence denotes ClinicalTrials.gov: NCT00981877.

LitCoin-PubTator-for-Tuning

Id Subject Object Predicate Lexical cue tao:has_database_id
3 23-44 ChemicalEntity denotes eicosapentaenoic acid MESH:D015118
4 46-62 ChemicalEntity denotes γ-linolenic acid MESH:D017965
5 106-112 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
74 264-285 ChemicalEntity denotes eicosapentaenoic acid MESH:D015118
75 287-290 ChemicalEntity denotes EPA MESH:D015118
76 292-308 ChemicalEntity denotes γ-linolenic acid MESH:D017965
77 310-313 ChemicalEntity denotes GLA MESH:D017965
78 358-366 OrganismTaxon denotes patients Tax:9606
79 379-390 DiseaseOrPhenotypicFeature denotes lung injury MESH:D055370
80 392-395 ChemicalEntity denotes EPA MESH:D015118
81 396-399 ChemicalEntity denotes GLA MESH:D017965
82 482-504 DiseaseOrPhenotypicFeature denotes pulmonary inflammation MESH:D011014
83 567-575 OrganismTaxon denotes patients Tax:9606
84 597-614 DiseaseOrPhenotypicFeature denotes acute lung injury MESH:D055371
85 736-739 ChemicalEntity denotes EPA MESH:D015118
86 740-743 ChemicalEntity denotes GLA MESH:D017965
87 793-801 OrganismTaxon denotes patients Tax:9606
88 813-819 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
89 888-897 DiseaseOrPhenotypicFeature denotes infection MESH:D007239
90 914-931 DiseaseOrPhenotypicFeature denotes organ dysfunction MESH:D019965
91 986-992 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
92 994-1000 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
93 1030-1043 DiseaseOrPhenotypicFeature denotes organ failure MESH:D009102
94 1048-1060 DiseaseOrPhenotypicFeature denotes septic shock MESH:D012772
95 1062-1068 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
96 1085-1096 DiseaseOrPhenotypicFeature denotes hypotension MESH:D007022
97 1194-1207 DiseaseOrPhenotypicFeature denotes organ failure MESH:D009102
98 1358-1366 OrganismTaxon denotes patients Tax:9606
99 1420-1427 GeneOrGeneProduct denotes EPA/GLA Gene:2717
100 1497-1503 ChemicalEntity denotes lipids MESH:D008055
101 1505-1513 OrganismTaxon denotes Patients Tax:9606
102 1634-1640 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
103 1648-1660 DiseaseOrPhenotypicFeature denotes septic shock MESH:D012772
104 1693-1706 DiseaseOrPhenotypicFeature denotes organ failure MESH:D009102
105 1816-1824 OrganismTaxon denotes patients Tax:9606
106 1848-1854 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
107 1977-1985 OrganismTaxon denotes patients Tax:9606
108 1994-1997 ChemicalEntity denotes EPA MESH:D015118
109 1998-2001 ChemicalEntity denotes GLA MESH:D017965
110 2029-2035 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
111 2043-2055 DiseaseOrPhenotypicFeature denotes septic shock MESH:D012772
112 2061-2069 OrganismTaxon denotes patients Tax:9606
113 2185-2193 OrganismTaxon denotes patients Tax:9606
114 2276-2284 OrganismTaxon denotes patients Tax:9606
115 2314-2336 DiseaseOrPhenotypicFeature denotes cardiovascular failure MESH:D002318
116 2386-2405 DiseaseOrPhenotypicFeature denotes respiratory failure MESH:D012131
117 2535-2543 OrganismTaxon denotes patients Tax:9606
118 2551-2559 OrganismTaxon denotes patients Tax:9606
119 2570-2592 DiseaseOrPhenotypicFeature denotes cardiovascular failure MESH:D002318
120 2642-2661 DiseaseOrPhenotypicFeature denotes respiratory failure MESH:D012131
121 2726-2734 OrganismTaxon denotes patients Tax:9606
122 2743-2746 ChemicalEntity denotes EPA MESH:D015118
123 2747-2750 ChemicalEntity denotes GLA MESH:D017965
124 2838-2846 OrganismTaxon denotes patients Tax:9606
125 2903-2911 OrganismTaxon denotes patients Tax:9606
126 2959-2967 OrganismTaxon denotes Patients Tax:9606
127 2987-2994 GeneOrGeneProduct denotes EPA/GLA Gene:2717
128 3064-3072 OrganismTaxon denotes patients Tax:9606
129 3156-3164 OrganismTaxon denotes patients Tax:9606
130 3274-3282 OrganismTaxon denotes patients Tax:9606
131 3376-3384 OrganismTaxon denotes patients Tax:9606
132 3577-3585 OrganismTaxon denotes patients Tax:9606
133 3593-3600 GeneOrGeneProduct denotes EPA/GLA Gene:2717
134 3673-3680 GeneOrGeneProduct denotes EPA/GLA Gene:2717
135 3775-3782 GeneOrGeneProduct denotes EPA/GLA Gene:2717
136 3844-3852 OrganismTaxon denotes patients Tax:9606
137 3876-3882 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
138 3902-3919 DiseaseOrPhenotypicFeature denotes organ dysfunction MESH:D019965
139 3966-3972 DiseaseOrPhenotypicFeature denotes sepsis MESH:D018805
140 3981-3998 DiseaseOrPhenotypicFeature denotes organ dysfunction MESH:D019965
141 4045-4068 DiseaseOrPhenotypicFeature denotes respiratory dysfunction MESH:D012131

LitCoin-Disease-Tuning-1

Id Subject Object Predicate Lexical cue ID:
T1 106-112 DiseaseOrPhenotypicFeature denotes sepsis D018805
T2 379-390 DiseaseOrPhenotypicFeature denotes lung injury D055370
T3 409-421 DiseaseOrPhenotypicFeature denotes inflammatory DISEASE
T4 482-504 DiseaseOrPhenotypicFeature denotes pulmonary inflammation D011014
T5 597-614 DiseaseOrPhenotypicFeature denotes acute lung injury D055371
T6 813-819 DiseaseOrPhenotypicFeature denotes sepsis D018805
T7 821-860 DiseaseOrPhenotypicFeature denotes systemic inflammatory response syndrome D018746
T8 888-897 DiseaseOrPhenotypicFeature denotes infection D007239
T9 949-975 DiseaseOrPhenotypicFeature denotes progression of the disease D018450
T10 979-992 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T11 994-1000 DiseaseOrPhenotypicFeature denotes sepsis D018805
T12 1048-1060 DiseaseOrPhenotypicFeature denotes septic shock D012772
T13 1062-1068 DiseaseOrPhenotypicFeature denotes sepsis D018805
T14 1085-1096 DiseaseOrPhenotypicFeature denotes hypotension D007022
T15 1627-1640 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T16 1648-1660 DiseaseOrPhenotypicFeature denotes septic shock D012772
T17 1848-1854 DiseaseOrPhenotypicFeature denotes sepsis D018805
T18 2022-2035 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T19 2043-2055 DiseaseOrPhenotypicFeature denotes septic shock D012772
T20 2386-2405 DiseaseOrPhenotypicFeature denotes respiratory failure D012131
T21 2642-2661 DiseaseOrPhenotypicFeature denotes respiratory failure D012131
T22 3876-3882 DiseaseOrPhenotypicFeature denotes sepsis D018805
T23 3966-3972 DiseaseOrPhenotypicFeature denotes sepsis D018805
T24 4045-4068 DiseaseOrPhenotypicFeature denotes respiratory dysfunction DISEASE

LitEisuke

Id Subject Object Predicate Lexical cue #label
T1 106-112 DiseaseOrPhenotypicFeature denotes sepsis D018805
T2 379-390 DiseaseOrPhenotypicFeature denotes lung injury D055370
T3 482-504 DiseaseOrPhenotypicFeature denotes pulmonary inflammation D011014
T4 597-614 DiseaseOrPhenotypicFeature denotes acute lung injury D055371
T5 813-819 DiseaseOrPhenotypicFeature denotes sepsis D018805
T6 821-860 DiseaseOrPhenotypicFeature denotes systemic inflammatory response syndrome D018746
T7 979-992 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T8 994-1000 DiseaseOrPhenotypicFeature denotes sepsis D018805
T9 1048-1060 DiseaseOrPhenotypicFeature denotes septic shock D012772
T10 1062-1068 DiseaseOrPhenotypicFeature denotes sepsis D018805
T11 1085-1096 DiseaseOrPhenotypicFeature denotes hypotension D007022
T12 1627-1640 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T13 1648-1660 DiseaseOrPhenotypicFeature denotes septic shock D012772
T14 1848-1854 DiseaseOrPhenotypicFeature denotes sepsis D018805
T15 2022-2035 DiseaseOrPhenotypicFeature denotes severe sepsis D018805
T16 2043-2055 DiseaseOrPhenotypicFeature denotes septic shock D012772
T17 2386-2405 DiseaseOrPhenotypicFeature denotes respiratory failure D012131
T18 2642-2661 DiseaseOrPhenotypicFeature denotes respiratory failure D012131
T19 3876-3882 DiseaseOrPhenotypicFeature denotes sepsis D018805
T20 3966-3972 DiseaseOrPhenotypicFeature denotes sepsis D018805
T21 4045-4068 DiseaseOrPhenotypicFeature denotes respiratory dysfunction DISEASE

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 678-685 HP_0000618 denotes blinded
T2 813-819 HP_0100806 denotes sepsis
T3 986-992 HP_0100806 denotes sepsis
T4 994-1000 HP_0100806 denotes sepsis
T5 1062-1068 HP_0100806 denotes sepsis
T6 1085-1096 HP_0002615 denotes hypotension

Allie

Id Subject Object Predicate Lexical cue
SS1_21658240_2_0 236-253 expanded denotes Enteral nutrition
SS2_21658240_2_0 255-257 abbr denotes EN
SS1_21658240_2_1 264-285 expanded denotes eicosapentaenoic acid
SS2_21658240_2_1 287-290 abbr denotes EPA
SS1_21658240_2_2 292-308 expanded denotes γ-linolenic acid
SS2_21658240_2_2 310-313 abbr denotes GLA
SS1_21658240_13_0 1925-1943 expanded denotes Intention-to-treat
SS2_21658240_13_0 1945-1948 abbr denotes ITT
AE1_21658240_2_0 SS1_21658240_2_0 SS2_21658240_2_0 abbreviatedTo Enteral nutrition,EN
AE1_21658240_2_1 SS1_21658240_2_1 SS2_21658240_2_1 abbreviatedTo eicosapentaenoic acid,EPA
AE1_21658240_2_2 SS1_21658240_2_2 SS2_21658240_2_2 abbreviatedTo γ-linolenic acid,GLA
AE1_21658240_13_0 SS1_21658240_13_0 SS2_21658240_13_0 abbreviatedTo Intention-to-treat,ITT